WP
SCPH

Woodline Partners’s scPharmaceuticals SCPH Stock Holding History

Woodline Partners’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-297,800
Closed -$1.05M – 1011
2024
Q4 		$1.05M Sell
297,800
-203,808
-41% -$781K 0.01% 750
2024
Q3 		$2.29M Buy
+501,608
New +$2.43M 0.02% 463

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Woodline Partners's SCPH Position: Q1 2025 in Review

Woodline Partners sold out of scPharmaceuticals (SCPH) in Q1 2025, closing a stake of 297,800 shares — an estimated $1.05M sold.

Woodline Partners first reported a position in SCPH in Q3 2024 and held it in 2 quarters. The position peaked at $2.29M in Q3 2024. 88 funds tracked by Wall St. Rank hold SCPH as of Q1 2025.

  • Woodline Partners reported no remaining scPharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 297,800 scPharmaceuticals shares in Q1 2025, an estimated $1.05M.
  • Woodline Partners first reported a position in scPharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Woodline Partners's scPharmaceuticals position peaked at $2.29M in Q3 2024.
  • 88 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.